Search Results

There are 4098 results for: content related to: Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  3. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  4. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Version of Record online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  5. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

    Hepatology

    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Version of Record online : 1 MAR 2012, DOI: 10.1002/hep.24791

  6. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Version of Record online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  7. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Version of Record online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  8. You have free access to this content
    Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

    Hepatology

    Volume 53, Issue 5, May 2011, Pages: 1742–1751, Jean-Michel Pawlotsky

    Version of Record online : 22 APR 2011, DOI: 10.1002/hep.24262

  9. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Version of Record online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  10. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546

  11. You have free access to this content
    Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 1709–1718, Simone Susser, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, Robert Ralston, Xiao Tong, Eva Herrmann, Stefan Zeuzem and Christoph Sarrazin

    Version of Record online : 4 AUG 2009, DOI: 10.1002/hep.23192

  12. You have free access to this content
    Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

    Hepatology

    Volume 56, Issue 5, November 2012, Pages: 1622–1630, Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner and Joan Butterton

    Version of Record online : 14 OCT 2012, DOI: 10.1002/hep.25831

  13. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  14. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Version of Record online : 4 FEB 2015, DOI: 10.1002/jcph.454

  15. You have free access to this content
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Version of Record online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  16. You have free access to this content
    Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 1, February 2014, Pages: 14–24, C. Park, S. Jiang and K. A. Lawson

    Version of Record online : 16 NOV 2013, DOI: 10.1111/jcpt.12106

  17. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir

    Alimentary Pharmacology & Therapeutics

    Volume 41, Issue 7, April 2015, Pages: 671–685, R. K. Sterling, A. Kuo, V. K. Rustgi, M. S. Sulkowski, T. G. Stewart, J. M. Fenkel, H. El-Genaidi, M. A. Mah'moud, G. M. Abraham, P. W. Stewart, L. Akushevich, D. R. Nelson, M. W. Fried and A. M. Di Bisceglie

    Version of Record online : 28 JAN 2015, DOI: 10.1111/apt.13095

  18. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 92A–207A,

    Version of Record online : 1 OCT 2013, DOI: 10.1002/hep.26726

  19. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  20. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046